120008-73-3

Upstream product

• 13404-22-3 tert-butyl L-alaninate hydrochloride 
• 99197-90-7 ethyl 4-(1-benzyloxycarbonyl-4-piperidyl)-2-oxobutyrate 

Downstream Products

• 120008-74-4 N-[1(S)-ethoxycarbonyl-3-(1-benzyloxycarbonyl-4-piperidyl)propyl]-L-alanyl-L-proline benzylester 
• 120008-90-4 4-[(S)-3-((S)-1-Carboxy-ethylamino)-3-ethoxycarbonyl-propyl]-piperidine-1-carboxylic acid benzyl ester 
• 120008-74-4 4-{(R)-3-[(S)-2-((S)-2-Benzyloxycarbonyl-pyrrolidin-1-yl)-1-methyl-2-oxo-ethylamino]-3-ethoxycarbonyl-propyl}-piperidine-1-carboxylic acid benzyl ester 
• 120008-90-4 4-[(R)-3-((S)-1-Carboxy-ethylamino)-3-ethoxycarbonyl-propyl]-piperidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Synthesis and angiotensin converting enzyme inhibitory activity of N-carboxymethyldipeptides with ω-(4-piperidyl)alkyl group

The synthesis of a series of novel, potent angiotensin converting enzyme (ACE) inhibitors containing 1(S)-carboxy-ω-(4-piperidyl)alkyl group at the N-terminal of the dipeptide is described. These 1-carboxy-ω-(4-piperidyl)alkyl derivatives possess greater or equivalent in vitro potency and in vivo efficacy than captopril and enalapril. The length (n) of the carbon chain in the ω-(4-piperidyl)alkyl moiety was varied from two to six to investigate the optimal structure for long-acting ACE inhibitors. 1-[N-[1(S)-Carboxy-6-(4-piperidyl)hexyl]-L-alanyl]-(2α,3aβ,7aβ)-oct ahydro-1H-indole-2-carboxylic acid, the most potent member of the series, had an in vivo area under the curve (AUC) of 685, which was calculated by the inhibition of angiotensin I-induced pressor response vs. time curves (0 to 8 h) after p.o. administration.